- The market for vectorized antibodies is gaining strong momentum, with companies such as Regeneron and Moderna actively developing in vivo expression platforms. These platforms allow the body to produce therapeutic antibodies internally, reducing the need for repeated injections or infusions
- Advanced delivery methods such as adeno-associated virus vectors and lipid nanoparticles are being applied by companies such as Spark Therapeutics and BioNTech
- For instance, BioNTech is exploring lipid nanoparticle-based delivery systems to enable the body to generate its own antibodies against cancer cells
- Real-world research instance has demonstrated the potential of this approach
- For instance, the University of Pennsylvania conducted a study in which a single administration of a vectorized antibody led to sustained therapeutic levels in animal models for hemophilia and certain cancers
- Collaborative initiatives are playing a major role in accelerating innovation
- For instance, the University of California partnered with Genentech to co-develop long-lasting and less invasive treatments for autoimmune and neurological diseases using in vivo antibody expression technologies
- Regulatory agencies are increasingly supportive of these developments
- For instance, the U.S. Food and Drug Administration has recently approved investigational new drug applications submitted by biotechnology companies for experimental vectorized antibody treatments targeting rare pediatric conditions
